Currently Viewing:
Currently Reading
FDA Approves Gene Therapy With $2.1M Price Tag for Spinal Muscular Atrophy in Pediatric Patients
May 24, 2019 – Jaime Rosenberg
Evobrutinib Reduced Signs of Active Inflammation in Patients with Multiple Sclerosis
May 24, 2019 – Wallace Stephens
AJMC® in the Press, May 24, 2019
May 24, 2019 – AJMC Staff
5 Key Policy Issues for Employers and Mental Health
May 24, 2019 – Mary Caffrey
What We're Reading: Bipartisan Healthcare Package; Colorado Caps Insulin Prices; FDA Authorizes Zika Diagnostic Test
May 24, 2019 – AJMC Staff
This Week in Managed Care: May 24, 2019
May 24, 2019
Suspension of a Rural Syringe Service Program Increased Risks of HIV and HCV Acquisition
May 23, 2019 – Wallace Stephens
How Cells Slow Cancer That Has Reached Bone
May 23, 2019 – Laura Joszt
LifeScan Finds Partner to Move Into CGM Market
May 23, 2019 – Mary Caffrey

Dana-Farber, Philips Partner to Expand Clinical Pathways Tool

Samantha DiGrande
The Dana-Farber Cancer Institute recently announced that it is partnering with Royal Philips in order to establish and provide improved clinical pathways in cancer care.
The Dana-Farber Cancer Institute recently announced that it is partnering with Royal Philips in order to establish and provide improved clinical pathways in cancer care.

Experts at Dana-Farber have developed a clinical pathways tool in order to deliver the latest data and treatment options to oncologists to provide patients with the best care possible. “Cancer care is just getting more complex, as a clinician has to factor in genomic data and think about all these new drug approvals that are coming fast and furious,” said David Jackman, MD, medical director for clinical pathways at Dana-Farber Cancer Institute, in an interview with

The clinical pathways tool acts as a data-driven map to help identify and navigate the best treatment options available for each cancer type at a particular stage. The pathways developed by Dana-Farber will be implemented through the Philips IntelliSpace Oncology Platform, a cloud-based system that integrates radiology, pathology, genomics, and electronic health record (EHR) data. 

“Cancer medicine is changing rapidly, and physicians are tasked with interpreting massive amounts of new information generated from publications and clinical trials. Through this collaboration with Philips, we can help them choose the best possible treatment for patients based on specific information and the deep experience of our clinicians,” said Laurie Glimcher, MD, president and CEO of Dana-Farber, in a statement.

The idea behind developing the pathways tool, according to Jackman, was to determine the best care for a patient in a given situation and try to capture all of that expertise and circulate that knowledge throughout the health system. That way, no matter where a patient is seen, they will receive the same answer about their care instead of a variety of suggestions. Through this program, the organization has been able to capture and share best practices for over 30 different diseases within medical and radiation oncology.

Given the many changes and updates to cancer care, Dana-Farber experts update the guidelines regularly. In addition to providing support in shared-decision making, the tool also helps physicians understand which clinical trials, if any, may be appropriate for each patient.

The collaboration with Dana-Farber and Philips will allow the clinical pathways tool to be made available to oncologists in this network and beyond, which will in turn enable providers to deliver innovative, evidence-based, and patient-centric care.

Related Articles

Dana-Farber Clinical Pathways Saved Costs, Maintained Outcomes in NSCLC
Clinical Pathways in NSCLC
Kathleen Lokay: Implementing Value in Clinical Pathways
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up